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Azithromycin levels in tonsillar and/or adenoid tissue were determined in children
(1.6-7.5 years old) who were scheduled for surgical removal of their tonsils and/or
adenoids. The children received azithromycin oral suspension lOmg/kg once daily
for 3 days. Tissue samples were obtained during surgery 1 (n = 4), 2 (n = 5), 4
(n = 6), or 8 (n = 5) days after the last dose of azithromycin. Serum samples were
also obtained from four children in each of these groups at the time of surgery. Mean
tissue concentrations of azithromycin were 10.33 ± 3.01, 7.21 ± 4.04, 9.30 ± 3.74
and 1.49 ± 0.48 mg/kg, respectively, 1, 2, 4 and 8 days after the last dose. At the
corresponding times, serum concentrations were markedly lower: 47.25 + 19 19,
14.00 ± 8.45, 8.00 ±2.16 and <4^g/L, respectively. The mean tissue:serum
concentration ratios were, 227 ± 54, 547 ± 184 and 956 ± 355, respectively, 1, 2 and
4 days after treatment. No adverse events attributable to azithromycin were observed
in any of the 23 children who had received at least one dose of azithromycin. The
study shows that levels of azithromycin in tonsillar and adenoid tissue were
consistently higher than in serum and remained elevated up to 8 days after the end
of dosing, supporting the use of a short-course (3-day), once-daily regimen of
azithromycin in the treatment of upper respiratory tract infections.
Introduction
Infectious pharyngitis/tonsillitis is very common in children. This condition, when of
bacterial aetiology, is usually caused by Streptococcus pyogenes and is a major
indication for the prescribing of oral antibacterial agents. Otitis media is another
childhood upper respiratory tract infection that is frequently encountered in clinical
practice, for which Haemophilus influenzae, Streptococcus pneumoniae and Moraxella
catarrhalis are the most common pathogens.
Standard therapy for streptococcal pharyngitis has been a 10-day oral regimen of
penicillin V, given up to four times daily, and for otitis media the standard is a 10-day
regimen of amoxycillin or ampicillin given three or four times daily. A 10-day,
multiple-daily course of erythromycin has been used as an alternative when there is
hypersensitivety to penicillins. However, the use of erythromycin has been limited,
particularly in adults, by the high incidence of gastrointestinal side-effects (Pilot & Qin,
1988; Pechere, 1993). Furthermore, the protracted multiple-dose regimens of both
45
03O5-7453/96/37CO45 + 07 $12.00/0 % 1996 The British Society for Antimicrobial Chemotherapy
46 B. P. Vaudaux ft at.
penicillins and erythromycin may, particularly in children, result in poor compliance,
with detrimental effects on treatment outcome.
Azithromycin is a macrolide antibacterial agent, structurally related to erythromycin
(Bright et al., 1988), but with improved in-vitro activity against Gram-negative
pathogens, such as H. influenzae (Retsema et al., 1987) and M. catarrhalis (Hardy
et al., 1988), and good activity against other pathogens, including S. pyogenes and
S. pneumoniae (Retsema et al., 1987).
Studies in adults have shown that the pharmacokinetic profile of azithromycin is
characterized by high tissue concentrations, which are frequently more than 100 times
those in serum. Azithromycin levels of 4.5 mg/kg have been achieved in tonsillar tissue,
with a half-life of 76 h after two 250-mg doses at a 12-h interval (Foulds et al., 1991).
Extrapolations from these data established that once-daily dosing with 500 mg
azithromycin for 3 days would maintain tonsillar levels of azithromycin at more than
2 mg/L for over 10 days, which is above the MIG» of azithromycin against common
upper respiratory tract pathogens (Foulds & Johnson, 1993).
This open-label study was designed to investigate azithromycin concentrations in the
tonsils and/or adenoids of children scheduled for surgical removal of these tissues. The
objectives were to confirm the pharmacokinetics of azithromycin determined in adults
and support the use of a 3-day, once-daily oral dosage regimen in the treatment of upper
respiratory tract infections.
Patients and methods
Patient selection
Children, of either sex, aged between 2 and 8 years, who were scheduled for surgical
removal of their tonsils and/or adenoids were eligible for the study. The children had
to be within the normal height and weight ranges for their age. Children were excluded
from the study if they had a history of sensitivity to any macrolide antibiotic, had any
condition that might affect drug absorption, were receiving or had received any other
antimicrobial agent in the previous week, had received any experimental drug in the
previous 4 weeks, or had evidence or a history of significant haematological, renal,
hepatic, or cardiovascular disease.
Study design
This study was conducted with the approval of the institutional review board. After
written informed consent had been obtained from the child's parents or legal guardian,
a medical history was recorded and a physical examination performed. Children were
allocated to one of four groups (groups I-IV) depending upon whether surgery was
scheduled for 1, 2, 4 or 8 days after the final dose of azithromycin.
Parents or guardians were provided with bottles containing powder for oral
suspension of azithromycin (900 mg/bottle); this was reconstituted in the investigator's
office by adding 12 mL water. The child's parents or guardian were provided with a
calibrated syringe so that the volume of suspension given could be precisely measured.
Children received azithromycin oral suspension 10 mg/kg once daily for 3 consecutive
days, 90 min before the evening meal. The parents or guardian were instructed to record
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the amount of azithromycin given and the time of administration so that compliance
could be monitored.
Azithromycin assay
Tissue and serum samples obtained at surgery were immediately frozen at — 50°C until
the analysis could be performed. Azithromycin concentrations were determined by
high-performance liquid chromatography with electrochemical detection (Shepard
et al., 1987) at the Clinical Pharmacology Division of the Geneva University Hospital.
The lower limit of detection of azithromycin in serum was considered to be 4 /ig/L and
in tissue 75
Safety
All adverse events, whether reported spontaneously by the child, their parents or
guardian, or observed by the investigator were recorded with details of day of onset,
duration, severity (mild, moderate or severe), outcome and relationship to treatment
(related, not related or uncertain/unknown).
Laboratory tests were performed before the first dose of study medication and at the
time of surgery.
Statistical analysis
As this was an open-label non-randomized study only general descriptive statistics were
used. Azithromycin tissue concentrations were calculated in mg/kg and serum
concentrations in j/g/L. One-way analysis of variance was used to compare mean
azithromycin concentrations between groups (Spjotvol & Stoline, 1973).
Results
Patients
In total, 26 children were enroled in the study; of these 23, 1.6-7.5 years of age, received
at least one dose of azithromycin. The baseline characteristics of children who received
at least one dose of azithromycin are summarized in Table I. There were no significant
differences in mean age, weight or height between the groups. Adenoidal hypertrophy
was the reason for surgery in 21 children and five of these also had tonsillar
Table I. Baseline characteristics of patients
Characteristic
Male
Female
Mean age ± S.D.
Mean weight ± s
Mean weight ± s
(years)
•D. (kg)
.D. (cm)
(n
4.2
15.1
104
I
=
3
3
±
-|-
±
6)
1.2
1.9
7
(«
4.9
19.0
111
Group
II
=
4
2
±
t
±
6)
1.6
4.2
8
1
5
18,
11
In
.5
9
3
III
=
4
2
±
±
±
6)
2.3
4.2
16
("
5.1
18.2
109
IV
=
3
2
±
-f-
±
5)
2.2
5.3
13
Total
(«
4.9
17.8
109
=
14
9
±
t
±
23)
1.8
4.1
11
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hypertrophy; two children had tonsillar hypertrophy alone. Of these 23 children, 16 also
had secretory otitis media.
In all, 21 children took the complete three-dose course of azithromycin. One patient
in group I received only the second and third doses of azithromycin and another patient
from group II was withdrawn after receiving one dose of azithromycin because of
unrelated adverse events; both these patients were excluded from the statistical analysis
of tissue and serum levels.
Patients in group I received their final doses of azithromycin 16—20 h (mean 17 h)
before surgery, in group II the times to surgery were 39-63 h (mean 46 h) after dosing,
in group III 88-91 h (mean 90 h) elapsed and in group IV 182-188 h (mean 185 h).
Azithromycin tissue concentrations
Azithromycin tissue concentrations were determined for 20 patients who received all
three doses of azithromycin: four from tissues removed at 1 day post-treatment, five
at 2 days; six at 4 days and five at 8 days (Table II). The azithromycin levels of one
child assigned to group I (last dose of azithromycin 24 h before surgery) could not be
assessed as her operation was cancelled. Adenoid tissue only was used from 15 patients,
tonsillar tissue only from one patient and both tissues from four patients.
Concentrations in adenoid and tonsillar tissue were similar. Mean azithromycin
concentrations were 10.33 ±3.01, 7.21 ± 4.04, 9.30 ± 3.74 and 1.49 ± 0.48 mg/kg,
respectively, at 1, 2, 4 and 8 days after the final azithromycin dose. The ranges of
azithromycin tissue levels 1, 2, 4 and 8 days after treatment were, respectively,
7.40-14.20, 2.00-11.50, 4.90-15.20 and 1.00-2.10 mg/kg. There was no significant
difference in mean azithromycin levels between tissues taken at 4 days post-treatment
and those obtained after 1 or 2 days. Azithromycin levels 8 days after treatment were
significantly lower (P < 0.005) than those 1 day post-treatment: at the earlier
assessments all tissue azithromycin concentrations were 2 mg/kg or more, whereas for
the 8-day assessment tissue concentrations were between 1 and 2 mg/kg in all except
one patient.
Azithromycin serum concentrations
Serum samples were obtained at the time of surgery from four children in each group.
Mean serum azithromycin levels were 47.25 ± 19.19, 14.00 ± 8.45, 8.00 ±2.16 and
< 4 ^g/L, respectively, at 1, 2, 4 and 8 days post-treatment. In contrast to tissue levels,
serum concentrations were highest 1 day after the end of treatment and progressively
decreased until after 8 days they were below the limits of detection.
Tissue:serum concentration ratios
Tissue:serum concentration ratios ranged from 187 to 302, 300 to 733 and 600 to 343,
respectively, 1, 2 and 4 days post-treatment; the ratio could not be established in tissues
assessed after 8 days because serum levels were below the limits of detection. The ratio
was highest in the group assayed 4 days after treatment and was significantly higher
(P < 0.005) than at 1 day after treatment.
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Safety
None of the 23 patients who received at least one dose of azithromycin experienced
adverse events attributable to azithromycin. One patient from group II, whose serum
transaminases had been elevated before treatment, experienced nausea, vomiting,
abdominal pain and diarrhoea on the day after the first dose of azithromycin. These
adverse events were considered to be due to a mild concurrent hepatitis A infection and
unrelated to study treatment. This patient was withdrawn from treatment after receiving
one dose of azithromycin.
Discussion
A previous pharmacokinetic study has been conducted in adults given two 250-mg doses
of azithromycin 12 h apart (Foulds et al., 1991). Pharmacokinetic modelling of data
from that and other studies (Foulds & Johnson, 1993) have suggested that a 3-day,
once-daily regimen of 500 mg azithromycin maintains tonsillar levels of azithromycin
above 2 mg/L for more than 10 days. The current study demonstrated that in children
a 3-day, once-daily course of oral azithromycin achieved high azithromycin
concentrations in tonsillar and/or adenoid tissue that were maintained for 8 days after
the end of treatment and that the values were consistent with those predicted in adults.
As in adults, azithromycin levels in tissue were consistently many times higher than in
serum.
In this study, tonsillar and/or adenoid azithromycin levels exceeded the MIC%s for
many upper respiratory tract pathogens, including S. pyogenes (0.1 mg/L; Retsema
et al., 1987), H. influenzae (0.78 mg/L; Retsema et al., 1987), M. catarrhalis
(0.03-0.06 mg/L; Hardy et al., 1988) and S. pneumoniae (0.05 mg/L; Retsema et al.,
1987), for up to 8 days after the end of treatment. Thus, the study supports the use of
short-course, once-daily azithromycin regimens in children for the treatment of upper
respiratory tract infections. A number of studies have already demonstrated the clinical
efficacy of such 3-day, once-daily regimens of azithromycin in the treatment of upper
respiratory tract infections in both children (Hamill, 1993; Weippl, 1993; Bottaro el al.,
1994) and adults (Muller, 1993), indicating that the high levels of azithromycin in the
tissues of the upper respiratory tract produce clinical benefits.
For some years, it has been known that both adults (Gatley, 1968) and children
(Bergman & Werner, 1963) are poorly compliant with anti-infective regimens that are
more than one week in duration and involve multiple-daily dosing. The reasons are
numerous, but the duration and frequency of dosing are among the most important
(Greenberg, 1984; Cockburn et al., 1987). Colcher & Bass (1972) showed that poor
compliance is likely to lead to an unsatisfactory clinical outcome. An anti-infective
agent with a simple dosing regimen, preferably once daily, combined with a short
duration of treatment should improve patient compliance and ultimately clinical
outcome. Azithromycin should, therefore, be more effective in the non-clinical trial
environment than antibacterials with more prolonged and complex treatment regimens.
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